导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.36% | 2293/4773 |
| 近一周 | -2.80% | 3130/5462 |
| 近一月 | -6.89% | 3669/5421 |
| 近一季 | -13.07% | 3936/5209 |
| 近半年 | -5.10% | 2734/4920 |
| 近一年 | 3.90% | 1831/4366 |
| 近两年 | 69.44% | 984/2954 |
| 近三年 | 38.69% | 751/2253 |
| 成立以来 | 48.26% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.59% 1871/4961 |
20.45% 1224/5312 |
- - |
- - |
| 2025 | 31.43% 1238/4813 |
1.34% 1647/3635 |
0.79% 2564/4076 |
28.29% 1273/4524 |
0.30% 2070/4813 |
| 2024 | 12.56% 1234/3463 |
-0.90% 1151/2808 |
-4.07% 1463/3014 |
18.40% 1013/3129 |
- 1287/3463 |
| 2023 | -11.52% 1408/2656 |
5.74% 757/2280 |
-4.13% 1064/2385 |
-7.34% 1557/2515 |
-5.81% 1510/2655 |
| 2022 | -24.43% 1215/2207 |
-17.92% 1283/1919 |
7.11% 529/2016 |
-15.40% 1283/2113 |
1.61% 1202/2208 |
| 2021 | 6.82% 507/1822 |
-4.36% 859/1255 |
12.74% 313/1330 |
-4.03% 677/1466 |
3.23% 459/1822 |
| 2020 | 44.10% 233/1250 |
-3.82% 324/1028 |
20.89% 256/1067 |
9.77% 624/1164 |
12.92% 415/1184 |
| 2019 | 46.79% 130/1092 |
35.58% 91/754 |
-5.56% 474/804 |
3.75% 233/850 |
10.49% 127/918 |
| 2018 | -31.58% 499/834 |
- - |
- - |
- - |
-12.85% 486/691 |
| 2017 | 11.76% 293/714 |
- - |
- - |
- - |
- - |
| 2016 | -18.44% 418/605 |
- - |
- - |
- - |
- - |
| 2015 | 10.47% 160/575 |
- - |
- - |
- - |
- - |
| 2014 | 35.25% 146/237 |
- - |
- - |
- - |
- - |
| 2013 | -10.08% 153/186 |
- - |
- - |
- - |
- - |
| 2012 | 3.15% 90/140 |
- - |
- - |
- - |
- - |
| 2011 | -27.55% 82/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 融通深证成份指数A VS. 长安沪深300非周期A(740101) |